Profile data is unavailable for this security.
About the company
Race Oncology Limited is an Australia-based precision oncology company with a Phase II/III cancer drug called Zantrene. Zantrene is a potent small molecule inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. The Company is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma (kidney cancer), which are both frequent FTO-driven cancers. Zantrene (bisantrene dihydrochloride) is a small molecule anti-cancer drug which has clinical and preclinical efficacy as both a low dose, highly targeted precision oncology agent and a cardio-protective chemotherapeutic. The Company also has clinical data for the use of Zantrene as a chemotherapeutic agent with reduced cardiotoxicity in acute myeloid leukemia (AML), breast and ovarian cancers and is investigating its use in these areas.
- Revenue in AUD (TTM)885.59k
- Net income in AUD-11.17m
- Incorporated2011
- Employees--
- LocationRace Oncology LtdLevel 36, Gateway 1, Macquarie PlaceSYDNEY 2000AustraliaAUS
- Phone+61 28051-3043
- Websitehttps://www.raceoncology.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Arovella Therapeutics Ltd | 139.02k | -10.23m | 120.77m | 14.00 | -- | 33.39 | -- | 868.71 | -0.0127 | -0.0127 | 0.0002 | 0.0034 | 0.0249 | -- | 15.15 | -- | -182.82 | -77.12 | -276.07 | -93.26 | 83.56 | 63.41 | -7,357.19 | -1,471.57 | -- | -- | 0.00 | -- | 45.47 | 0.3491 | -18.11 | -- | -68.72 | -- |
PharmAust Limited | 1.85m | -7.79m | 126.19m | 52.00 | -- | 16.04 | -- | 68.17 | -0.0236 | -0.0201 | 0.0055 | 0.02 | 0.1977 | -- | 6.71 | -- | -83.26 | -25.56 | -96.46 | -28.78 | 20.06 | 90.73 | -421.04 | -59.16 | -- | -104.65 | 0.00 | -- | -13.53 | 3.42 | -263.63 | -- | -47.47 | -- |
Vita Life Sciences Limited | 74.16m | 9.08m | 134.34m | 124.00 | 14.52 | 3.13 | 14.01 | 1.81 | 0.166 | 0.166 | 1.36 | 0.7695 | 1.33 | 2.34 | 7.35 | -- | 16.27 | 15.25 | 22.51 | 21.99 | 58.14 | 60.90 | 12.24 | 11.71 | 2.29 | -- | 0.0089 | 39.05 | 10.88 | 12.50 | 28.18 | 30.07 | 12.15 | 19.14 |
Next Science Ltd | 34.47m | -25.29m | 137.10m | -- | -- | 6.88 | -- | 3.98 | -0.1093 | -0.1093 | 0.1473 | 0.0683 | 1.46 | 7.47 | 8.33 | -- | -107.19 | -74.40 | -136.06 | -90.31 | 73.20 | 76.98 | -73.36 | -128.26 | 3.45 | -50.37 | 0.0698 | -- | 89.36 | 50.80 | -28.29 | -- | -2.28 | -- |
Proteomics International LaboratoriesLtd | 1.44m | -5.90m | 146.60m | -- | -- | 25.60 | -- | 101.46 | -0.0518 | -0.0518 | 0.0129 | 0.0437 | 0.1817 | -- | 11.13 | -- | -75.75 | -57.79 | -87.11 | -67.57 | -- | -- | -416.78 | -229.69 | -- | -283.47 | 0.0088 | -- | -14.64 | 4.12 | -24.20 | -- | 89.02 | -- |
Dimerix Ltd | 181.28k | -10.87m | 159.38m | 0.00 | -- | 71.98 | -- | 879.20 | -0.0294 | -0.0294 | 0.0005 | 0.004 | 0.0169 | -- | 0.7586 | -- | -101.36 | -70.77 | -128.88 | -110.81 | -- | -- | -5,994.52 | -61,882.73 | -- | -- | 0.4541 | -- | 1,452.32 | 12.76 | -31.57 | -- | -8.26 | -- |
Cogstate Ltd | 64.53m | 8.57m | 222.85m | 61.00 | 28.34 | 3.78 | 17.35 | 3.45 | 0.0459 | 0.0459 | 0.3497 | 0.3442 | 0.7757 | -- | 5.58 | -- | 10.30 | 6.01 | 13.84 | 9.22 | 54.69 | 51.50 | 13.28 | 7.26 | -- | -- | 0.0135 | 0.00 | -8.62 | 7.25 | -52.56 | -- | -5.06 | -- |
Race Oncology Ltd | 885.59k | -11.17m | 230.41m | -- | -- | 11.12 | -- | 260.18 | -0.069 | -0.069 | 0.0055 | 0.125 | 0.0336 | -- | 0.326 | -- | -42.44 | -43.50 | -43.67 | -45.25 | -- | -- | -1,261.86 | -5,058.82 | -- | -- | 0.00 | -- | 997.63 | 93.78 | 11.41 | -- | -- | -- |
Probiotec Ltd | 221.22m | 8.69m | 231.77m | 111.00 | 27.45 | 2.62 | 9.68 | 1.05 | 0.1038 | 0.1038 | 2.64 | 1.09 | 0.9483 | 7.03 | 6.99 | -- | 3.72 | 4.58 | 5.36 | 5.94 | 29.95 | 30.21 | 3.93 | 5.73 | 1.09 | 3.33 | 0.4937 | 47.90 | 17.39 | 23.10 | -19.61 | 20.84 | 12.97 | 18.77 |